Ionis Pharmaceuticals Prices $700 Million Convertible Senior Notes Offering
I'm PortAI, I can summarize articles.
Ionis Pharmaceuticals Inc. has priced a $700 million offering of 0.00% Convertible Senior Notes due 2030. The notes, maturing on December 1, 2030, will not bear regular interest. The company has granted an option for initial purchasers to buy an additional $70 million in notes. Net proceeds are expected to be approximately $682.8 million, which will be used for repurchasing existing notes and general corporate purposes.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments